| 000 | 01712 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517150114.0 | ||
| 264 | 0 | _c20180305 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.16567 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aXu, Chen | |
| 245 | 0 | 0 |
_aPoor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type. _h[electronic resource] |
| 260 |
_bOncotarget _cMay 2017 |
||
| 300 |
_a33185-33196 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadministration & dosage |
| 650 | 0 | 4 | _aBiomarkers, Tumor |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Grading |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xmetabolism |
| 650 | 0 | 4 |
_aStomach Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTrastuzumab _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aLiu, Yalan | |
| 700 | 1 | _aJiang, Dongxian | |
| 700 | 1 | _aLi, Qian | |
| 700 | 1 | _aGe, Xiaowen | |
| 700 | 1 | _aZhang, Ying | |
| 700 | 1 | _aHuang, Jie | |
| 700 | 1 | _aSu, Jieakesu | |
| 700 | 1 | _aJi, Yuan | |
| 700 | 1 | _aHou, Jun | |
| 700 | 1 | _aLu, Shaohua | |
| 700 | 1 | _aHou, Yingyong | |
| 700 | 1 | _aLiu, Tianshu | |
| 773 | 0 |
_tOncotarget _gvol. 8 _gno. 20 _gp. 33185-33196 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.16567 _zAvailable from publisher's website |
| 999 |
_c27060512 _d27060512 |
||